Literature DB >> 30899394

Long noncoding RNA HCP5 contributes to epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation and interacting with miR-139-5p.

Cheng Yang1, Junjun Sun1, Weifeng Liu1, Yanhui Yang1, Zhijie Chu1, Tianbao Yang1, Yang Gui1, Du Wang1.   

Abstract

Long noncoding RNAs (lncRNAs) play key roles in various malignancy pathogenesis. However, the mechanisms remain poorly understood in the development and progression of colorectal cancer (CRC). Here, we focused on the specific role of human leukocyte antigen (HLA) Complex P5 (HCP5) in CRC. Quantitative real-time PCR (qRT-PCR) analysis and western blot were used to assess the expression of HCP5 in CRC tissues. The association between the expressions of HCP5 and miR-139-5p was assessed by Pearson's correlation analysis. The prognosis of CRC patients was analyzed by Kaplan-Meier survival analysis. Specific siRNAs were stably transfected into CRC cells with lentivirus approaches. The proliferative, migrative and invasive capacities of CRC cells were detected by Transwell, MTT and scratch assay, respectively. Dual-luciferase assay was performed to measure miR-139-5p-targeted relationship with lncRNA HCP5. HCP5 overexpression and of miR-139-5p downregulation were dramatically correlated with low TNM stage, poor differentiation, low tumor depth invasion in CRC patients (P < 0.05). Besides, HCP5 overexpression or ZEB1 knockdown repressed Snail family transcriptional repressor (SNAI) and vimentin expressions, upregulated E-cadherin expression, and inhibited cell proliferation and metastasis (P < 0.05). Moreover, luciferase reporter assay demonstrated that miR-139-5p was a directly target of HCP5 (P < 0.05). Overall, the present study indicated that HCP5 played a key regulator in CRC development and progression by targeting HCP5/miR-139-5p/ZEB1 axis, which may serve as a novel therapeutic target for CRC therapy.

Entities:  

Keywords:  Colorectal cancer (CRC); human leukocyte antigen (HLA) complex P5 (HCP5); long noncoding RNAs (lncRNA); metastasis; miR-139-5p; proliferation

Year:  2019        PMID: 30899394      PMCID: PMC6413275     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  22 in total

1.  LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β-catenin/cyclin D1 signaling via PLAGL2.

Authors:  Qinhua Liu; Ruonan Ran; Mingyue Song; Xiaodan Li; Zhengsheng Wu; Guanrong Dai; Ruixiang Xia
Journal:  Cell Biol Toxicol       Date:  2021-07-31       Impact factor: 6.691

2.  LINC00665/miR-9-5p/ATF1 is a novel axis involved in the progression of colorectal cancer.

Authors:  Xuhong Zhao; Wenhao Weng; Yin Long; Weijie Pan; Zhi Li; Fenyong Sun
Journal:  Hum Cell       Date:  2020-08-10       Impact factor: 4.174

3.  LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling.

Authors:  Jianyu Xu; Jianli Ma; Bixi Guan; Jian Li; Yan Wang; Songliu Hu
Journal:  Cell Cycle       Date:  2021-06-30       Impact factor: 5.173

4.  Knockdown of lncRNA HCP5 Suppresses the Progression of Colorectal Cancer by miR-299-3p/PFN1/AKT Axis.

Authors:  Ni Bai; Ying Ma; Jia Zhao; Bo Li
Journal:  Cancer Manag Res       Date:  2020-06-19       Impact factor: 3.989

5.  Long non-coding RNA RP11-59H7.3 promotes cell proliferation and invasion metastasis in colorectal cancer by miR-139-5p/NOTCH1 axis.

Authors:  Xiaojian Zhu; Chen Luo; Fanqin Bu; Kang Lin; Zhengming Zhu
Journal:  Aging (Albany NY)       Date:  2020-06-06       Impact factor: 5.682

Review 6.  Long Noncoding RNA HCP5, a Hybrid HLA Class I Endogenous Retroviral Gene: Structure, Expression, and Disease Associations.

Authors:  Jerzy K Kulski
Journal:  Cells       Date:  2019-05-20       Impact factor: 6.600

7.  Long Noncoding RNA HCP5 Regulates Pancreatic Cancer Gemcitabine (GEM) Resistance By Sponging Hsa-miR-214-3p To Target HDGF.

Authors:  Yunfei Liu; Jiale Wang; Luo Dong; Li Xia; Hongwei Zhu; Zhiqiang Li; Xiao Yu
Journal:  Onco Targets Ther       Date:  2019-10-04       Impact factor: 4.147

8.  UTMD inhibit EMT of breast cancer through the ROS/miR-200c/ZEB1 axis.

Authors:  Dandan Shi; Lu Guo; Xiao Sun; Mengmeng Shang; Dong Meng; Xiaoying Zhou; Xinxin Liu; Yading Zhao; Jie Li
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

Review 9.  Controversies around epithelial-mesenchymal plasticity in cancer metastasis.

Authors:  Elizabeth D Williams; Dingcheng Gao; Andrew Redfern; Erik W Thompson
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

10.  MHC Class I Regulation: The Origin Perspective.

Authors:  Alicja Sznarkowska; Sara Mikac; Magdalena Pilch
Journal:  Cancers (Basel)       Date:  2020-05-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.